PD-1/PD-L1 Pathway Study on Septic Patients

Changhai Hospital39 enrolled

Overview

The investigators want to identify that whether PD-1/PD-L1 pathway will change in human sepsis, and whether PD-1/PD-L1 pathway play an important role in sepsis induced immunosuppression.

First, we will detect PD-L1 expression on PBMC of septic patients and healthy controls. Second, blockade of PD-1/PD-L1 pathway in vitro and stimulate with some biomolecules and then analyze the PBMC function and apoptosis by flow cytometry. Then, compare with healthy controls and find the differences.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Sepsis

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * patients who develop sepsis Exclusion Criteria: * patients with cirrhosis or renal dysfunction * patients with dyscrasia * patients with autoimmunity diseases * patients with severe cardiac and pulmonary diseases * patients with hematological diseases * patients with diabetes mellitus * patients with malignant tumors

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.